Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. CANADIAN NATIONAL STOCK EXCHANGE
  5. Defence Therapeutics Inc.
  6. Summary
    DTC   CA24463V1013

DEFENCE THERAPEUTICS INC.

(DTC)
 SummaryQuotesChartsNewsCompanyFinancials 
Quotes 5-day view   Delayed Quote. Delayed Canadian National Stock E…
01/20/2022 01/21/2022 01/24/2022 01/25/2022 01/26/2022 Date
5.15(c) 5(c) 4.95(c) 5.1(c) 5.16 Last
3 820 16 825 4 001 27 795 13 200 Volume
+3.00% -2.91% -1.00% +3.03% +1.18% Change
More quotes
Estimated financial data (e)
Sales 2020 - - -
Net income 2020 -0,67 M -0,54 M -0,54 M
Net cash position 2020 1,87 M 1,48 M 1,48 M
P/E ratio 2020 -
Yield 2020 -
Sales 2021 - - -
Net income 2021 -2,86 M -2,28 M -2,28 M
Net cash position 2021 5,45 M 4,34 M 4,34 M
P/E ratio 2021 -65,6x
Yield 2021 -
Capitalization 184 M 146 M 146 M
EV / Sales 2020 -
EV / Sales 2021 -
Nbr of Employees -
Free-Float -
More Financials
Company
Defence Therapeutics Inc. is a Canada-based biotechnology company. The Company’s principal business activity is the development of a biological drug enhancer platform for biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The Company is engaged in developing the vaccines and antibody drug conjugates (ADC) products. Its Accum Technology platform provides drug... 
Read more
More about the company
All news about DEFENCE THERAPEUTICS INC.
02:31aDEFENCE THERAPEUTICS INC. : Defence's AccumTM-HPV vaccine formulation (AccuVAC-PT009) acti..
EQ
01/10Defence therapeutics achieves a major milestone and begins ind-enabling testing of its ..
EQ
01/10Defence Therapeutics Inc. Begins Ind-Enabling Testing of its Accutox Lead Compound Agai..
CI
2021Defence Therapeutics Inc. Accum(TM) Boosts by 9-Fold the Delivery Effectiveness of CRIS..
CI
2021Defence therapeutics accumtm boosts by 9-fold the delivery effectiveness of the crispr/..
EQ
2021Defence therapeutics vaccines and program development
EQ
2021Defence therapeutics cancer vaccine accuvac-d001 manufacturing targets melanoma and bre..
EQ
2021Defence therapeutics appoints dr. riam shammaa to its board of directors
EQ
2021Defence Therapeutics Inc. Appoints Riam Shammaa to its Board of Directors
CI
2021VACCINE RESULTS : Defence therapeutics reports successful completion of its covid-19 vacci..
EQ
2021Defence Therapeutics Inc. Reports Successful Completion of its COVID-19 Vaccine AccuVAC..
CI
2021Defence Therapeutics Scores Again With New Planned Phase 1 Trial Evaluating Its DC Canc..
AQ
2021Defence Therapeutics Accumtm Variants in Vitro Study Increases the Potency of T-Deruxte..
CI
2021DEFENCE THERAPEUTICS INC. : Defence therapeutics accumtm variants in vitro study increases..
EQ
2021DEFENCE THERAPEUTICS ACCUM(TM) TECHN : Dtcff)
AQ
More news
News in other languages on DEFENCE THERAPEUTICS INC.
08:24aDEFENCE THERAPEUTICS INC. : Der auf Basis der AccumTM-Technologie von Defense formulierte ..
06:21aDEFENCE THERAPEUTICS INC. : Der auf Basis der AccumTM-Technologie von Defence formulierte ..
06:21aDEFENCE THERAPEUTICS INC. : Der auf Basis der AccumTM-Technologie von Defence formulierte ..
01/24DEFENCE THERAPEUTICS INC. (VON GBC A : -
01/11DEFENCE THERAPEUTICS INC. : Defence Therapeutics erreicht wichtigen Meilenstein mit Antikr..
More news
Chart DEFENCE THERAPEUTICS INC.
Duration : Period :
Defence Therapeutics Inc. Technical Analysis Chart | DTC | CA24463V1013 | MarketScreener
Income Statement Evolution
Managers and Directors
Sébastien Plouffe President, Chief Executive Officer & Director
P. Joseph Meagher Chief Financial Officer & Director
Raimar Löbenberg Chairman
Simon Beaudoin Chief Technology & Science Officer
Moutih Rafei Director & VP-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
DEFENCE THERAPEUTICS INC.-4.44%146
MODERNA, INC.-39.94%61 847
LONZA GROUP AG-20.30%49 060
IQVIA HOLDINGS INC.-16.27%45 129
SEAGEN INC.-19.08%22 875
ICON PUBLIC LIMITED COMPANY-19.15%20 381